FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
KEY POINTS In 2022, The College of Family Physicians of Canada (CFPC) published its final report of the Outcomes of Training Project, including the recommendation…
Advances in Therapy – According to current guidelines, targeted therapy with a combination of BRAF plus MEK inhibitors is the preferred first-line treatment for patients…
The world’s most influential people in health have made fresh discoveries, dreamed up novel treatments, and pioneered global victories over disease.
Former prime minister Boris Johnson was caught out by a law his own government introduced as he went to vote on Thursday
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
The nominations for this year’s The Pathologist Power List are open.
Disclosures. Kean:Merck EMD Serono: Research Funding; Novartis: Research Funding; Tessera: Research Funding; Vertex: Consultancy, Membership on an entity’s
The Food and Drug Administration is advising consumers not to purchase or use Artri King, a product promoted and sold for joint pain and arthritis…
The world’s most influential people in health have made fresh discoveries, dreamed up novel treatments, and pioneered global victories over disease.
Abstract. Oncogenesis and progression of pancreatic ductal adenocarcinoma (PDAC) is driven by complex interactions between the neoplastic component and the tumor microenvironment (TME), which includes…